Filter by Category: In Vitro Activity

Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens.

Activity of ceftolozane-tazobactam and comparators when tested against bacterial surveillance isolates collected from patients at risk of infections caused by resistant gram-negative pathogens. by Pfaller MA, Shortridge D, Arends SJR, Duncan LR, Streit JM and Flamm RK. published in Diag. Microbio. Infect. Dis. 2020; 98 (1): 115101.

Activity of Meropenem-Vaborbactam and Comparator Agents Tested against Enterobacterales Isolates from the United States Analyzed by Site of Infection

Activity of Meropenem-Vaborbactam and Comparator Agents Tested against Enterobacterales Isolates from the United States Analyzed by Site of Infection Lead author: D Shortridge presented at ASM Microbe 2020, June 18-22, Chicago IL, USA
Poster #3804

Activity of plazomicin tested against Enterobacterales isolates collected from U.S. Hospitals in 2016-2017: Effect of different breakpoint criteria on susceptibility rates among aminoglycosides.

Activity of plazomicin tested against Enterobacterales isolates collected from U.S. Hospitals in 2016-2017: Effect of different breakpoint criteria on susceptibility rates among aminoglycosides. by Castanheira M, Sader HS, Mendes RE and Jones RN. published in Antimicrob. Agents Chemother. 2020; 64 (5): e02418

In vitro activity of KBP-7072, a novel third-generation tetracycline, against 531 recent geographically diverse and molecularly characterized Acinetobacter baumannii species complex isolates.

In vitro activity of KBP-7072, a novel third-generation tetracycline, against 531 recent geographically diverse and molecularly characterized Acinetobacter baumannii species complex isolates. by Huband MD, Mendes RE, Pfaller MA, Lindley JM, Strand GJ, Benn VJ, Zhang J, Li L, Zhang M, Tan X, Liu Q and Flamm RK. published in Antimicrob. Agents Chemother. 2020; 64 (5): e02375

Activity of Omadacycline and Comparator Agents against Bacterial Pathogens from the United States by Infection Type (2019)

Activity of Omadacycline and Comparator Agents against Bacterial Pathogens from the United States by Infection Type (2019). Lead author: MD Huband. This poster was originally intended for presentation at ECCMID 2020, which was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book under abstract 1019.
Poster #P1143

Tedizolid Activity against a Global Collection of Gram-Positive Bacterial Isolates Causing Bone and Joint Infections (2017-2019)

Tedizolid Activity against a Global Collection of Gram-Positive Bacterial Isolates Causing Bone and Joint Infections (2017-2019). Lead author: CG Carvalhaes. This poster was originally intended for presentation at the 30th ECCMID (Paris, France; April 18-21, 2020). This meeting was canceled due to the COVID-19 pandemic. The corresponding accepted abstract can be found in the 30th ECCMID abstract book (Abstract 2359)
Poster #P1174

Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018.

Ceftobiprole activity against bacteria from skin and skin structure infections in the United States from 2016 through 2018. by Flamm RK, Duncan LR, Hamed KA, Smart JI, Mendes RE and Pfaller MA. published in Antimicrobial agents and chemotherapy. 2020; 64 (6): e02566

Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018.

Meropenem-vaborbactam activity against carbapenem-resistant Enterobacterales isolates collected in U.S. hospitals during 2016 to 2018. by Castanheira M, Doyle TB, Kantro V, Mendes RE and Shortridge D published in Antimicrob. Agents Chemother. 2020; 64 (2): 01951

Activity of meropenem-vaborbactam against bacterial isolates causing pneumonia in hospitalized patients from U.S. hospitals during 2014 to 2018

Activity of meropenem-vaborbactam against bacterial isolates causing pneumonia in hospitalized patients from U.S. hospitals during 2014 to 2018. by Carvalhaes CG, Shortridge D, Sader HS and Castanheira M. published in Antimicrobial agents and chemotherapy. in press, 2020.

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018). by Sader HS, Flamm RK, Carvalhaes CG and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2019; 96: 114833